Related Experiment Videos
Problem pathogens (Pseudomonas aeruginosa and Acinetobacter)
1Service de Réanimation Médicale, H pital Bichat-Claude Bernard, Paris, France. jean.chastre@bch.ap-hop-paris.fr
Abstract:
A number of factors have been suspected of or identified as increasing the risk for pneumonia or colonization of the lower respiratory tract by Pseudomonas and/or Acinetobacter spp. in the intensive care unit (ICU), including advanced age, chronic lung disease, immunosuppression, surgery, use of antimicrobial agents, presence of such invasive devices as endotracheal and gastric tubes, and type of respiratory equipment. However, there is little doubt that of all these factors, extended ICU care because of severe underlying disease, prolonged respiratory therapy with mechanical ventilation, and prior antimicrobial therapy are the most important. Because the only factor amenable to prevention in this setting is antimicrobial therapy, avoiding unnecessary antibiotics should be a high priority in the management of such patients. Crude mortality rates of 30% to 75% have been reported for nosocomial pneumonia caused by Pseudomonas and/or Acinetobacter spp., with the highest rates reported in ventilator-dependent patients. It is therefore clear that the prognosis associated with this type of infection is considerably worse than that associated with infection caused by other gram-negative or gram-positive bacteria. Because bactericidal synergy against Pseudomonas and Acinetobacter spp. has been shown when carbenicillin and an aminoglycoside are combined, the use of an effective beta-lactam (piperacillin, ticarcillin, ceftazidime, or imipenem) and aminoglycoside combination remains the preferred therapeutic approach when possible. Future research efforts should also aim to improve our ability to diagnose and exclude infection in the ICU setting to avoid administering unnecessary antibiotics to patients without true pulmonary infection.
Insights
Preventing unnecessary antibiotic use is crucial for managing intensive care unit (ICU) patients at high risk for Pseudomonas and Acinetobacter pneumonia. Early diagnosis and targeted therapy improve outcomes for these severe infections.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Hospital-Acquired Infections
Background:
- Intensive care unit (ICU) patients face increased risk of lower respiratory tract infections, particularly pneumonia, from Pseudomonas and Acinetobacter species.
- Key risk factors include prolonged ICU stay, mechanical ventilation, and prior antibiotic exposure, with advanced age and comorbidities also contributing.
- Nosocomial pneumonia caused by these gram-negative bacteria carries a high mortality rate, especially in ventilator-dependent patients.
Purpose of the Study:
- To highlight the critical importance of preventing unnecessary antibiotic administration in ICU patients.
- To emphasize the significant risks and poor prognosis associated with Pseudomonas and Acinetobacter pneumonia in the ICU.
- To advocate for improved diagnostic strategies to avoid overtreatment.
Main Methods:
- Review of risk factors associated with Pseudomonas and Acinetobacter colonization and pneumonia in the ICU setting.
- Analysis of reported mortality rates for nosocomial pneumonia caused by these specific pathogens.
- Discussion of current preferred therapeutic strategies, including combination antibiotic therapy.
Main Results:
- Extended ICU care, prolonged mechanical ventilation, and prior antibiotic therapy are identified as the most significant risk factors.
- Mortality rates for nosocomial pneumonia due to Pseudomonas and/or Acinetobacter spp. range from 30% to 75%, with higher rates in ventilator-dependent patients.
- Bactericidal synergy is demonstrated for beta-lactam and aminoglycoside combinations against these pathogens.
Conclusions:
- Avoiding unnecessary antibiotic therapy is the only preventable factor and should be a high priority in ICU patient management.
- Combination therapy with a beta-lactam (e.g., piperacillin, ceftazidime) and an aminoglycoside is the preferred treatment approach.
- Future research should focus on enhancing diagnostic accuracy to prevent unnecessary antibiotic use in non-infected ICU patients.